Skip to main content

Characterization of Users of Atogepant in TriNetX: A Descriptive Analysis

    Basic Details
    Date Posted
    Status
    Complete
    Medical Product
    atogepant
    Description

    In this report, we aimed to list the most frequent diagnoses, procedures, medications and labs associated with use of atogepant, a new molecular entity (NME) approved by the FDA in 2021 using the TriNetX Live™ platform. 

    We ran this query on May 29, 2024. This query contains data from 60 health care organizations (HCOs), provided through the TriNetX Live™ platform in their USA Network with Minimal Shift from December 18, 2020 to February 29, 2024.

    Additional Details
    FDA Center
    CDER
    Time Period
    December 18, 2020 - February 29, 2024
    Analysis Type
    TriNetX Analysis
    Population / Cohort
    All individuals
    Data Sources
    TriNetX USA Network